We are live on ! Find out more
PJP icon

Invesco Pharmaceuticals ETF

96 hedge funds and large institutions have $110M invested in Invesco Pharmaceuticals ETF in 2017 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 15 increasing their positions, 42 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more call options, than puts

Call options by funds: $621K | Put options by funds: $495K

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

1.46% less ownership

Funds ownership: 15.84%14.37% (-1.5%)

5% less funds holding

Funds holding: 10196 (-5)

18% less capital invested

Capital invested by funds: $134M → $110M (-$24.2M)

19% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 16

64% less repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 42

Holders
96
Holders Change
-5
Holders Change %
-4.95%
% of All Funds
2.38%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
13
Increased
15
Reduced
42
Closed
16
Calls
$621K
Puts
$495K
Net Calls
+$126K
Net Calls Change
+$553K

PJP Hedge Fund Activity: Q1 2017 in Review

96 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Invesco Pharmaceuticals ETF (PJP) for Q1 2017, worth a combined $110M — down 18% from $134M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of PJP and 13 opened new positions — a net loss of 3 holders — while 42 trimmed existing stakes and 15 added.

The largest buyer was Citadel Advisors, adding an estimated $1.63M. The largest seller was Bank of America, cutting an estimated $9.9M.

  • 96 institutional investors held Invesco Pharmaceuticals ETF (PJP) as of Q1 2017, down from 101 in Q4 2016.
  • Funds reported $110M of Invesco Pharmaceuticals ETF stock for Q1 2017, down 18% quarter-over-quarter.
  • 13 funds opened new Invesco Pharmaceuticals ETF positions in Q1 2017 and 16 closed out, a net change of -3 holders.
  • The largest Invesco Pharmaceuticals ETF buyer in Q1 2017 was Citadel Advisors, an estimated $1.63M added.
  • The largest Invesco Pharmaceuticals ETF seller in Q1 2017 was Bank of America, an estimated $9.9M sold.

Based on aggregated 13F filings for Q1 2017.